Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 214

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 214
---
 expect.

The timing and amount of our operating expenditures will depend largely on:

•the timing and progress of preclinical and clinical development activities;

•the number and scope of preclinical and clinical programs we decide to pursue;

•the timing and amount of milestone payments we may receive under any future collaboration agreements;

•our ability to maintain future licenses and research and development programs and to establish new collaboration and/or in-licensing arrangements;

•the costs involved in prosecuting and enforcing patent and other intellectual property claims;

•the cost and timing of regulatory approvals; and

•our efforts to manage our office and laboratory headquarters, enhance operational systems and hire additional personnel to support development of our product candidates and satisfy our obligations as a public company.

Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financing. We may also consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations or our ability to incur additional indebtedness or pay dividends, among other items. If we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially and adversely affect our business, financial condition, results of operations and prospects. 

 97

Cash Flows

The following table summarizes our cash flows for the period indicated (in thousands):

    Year Ended

    December 31,

    2024

    2023

    2022

    Cash used in operating activities
     
    $
    (51,282
    )
     
    $
    (55,657
    )
     
    $
    (63,760
    )

    Cash used in investing activities

    53,352

    (50,545
    )

    (1,368
    )

    Cash provided by financing activities